Generic launch was impossible, says Impax
Impax has argued in court that although it had bottled $1.5 million worth of Oxymorphone by June 2010, it wasn’t prepared to launch at risk because the company hadn’t made enough of the drug to last a month in the market.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10